In 2024, the diagnosed prevalent population of C3 glomerulopathy in the 7MM was approximately 5,800. This number is expected to rise through 2034, driven by advances in complement biology, improved ...

Amyndas Pharmaceuticals SA, which is committed to developing innovative therapeutics to treat complement-mediated disorders, announced today that its lead candidate, the C3 complement inhibitor ...

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...

For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of ...

C3G (Complement 3 Glomerulopathy) and IC-MPGN (Immune Complex Membranoproliferative Glomerulonephritis) are rare, incurable kidney diseases that have similar symptoms and progression. While these ...

Amyndas Pharmaceuticals S.A. is pleased to announce today that the Aplastic Anemia & MDS International Foundation (AA&MDSIF) is endorsing the clinical development of Amyndas' lead candidate AMY-101, ...

In this analysis of patients with myeloperoxidase-ANCA-positive AAV, all urinary complement C3 fragment levels were elevated significantly compared with healthy controls (P .01 for all). Specific ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to begin a Phase 1/2a clinical trial of ARO-C3, the ...

Suchandrima Bhowmik has written over 300 articles on various health conditions, medical news, and recent breakthroughs. Her work appears in several publications, including Medical News Today, ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s ...